MicroRNA 744-3p promotes MMP-9-mediated metastasis by simultaneously suppressing PDCD4 and PTEN in laryngeal squamous cell carcinoma by Lei, WB et al.
Title
MicroRNA 744-3p promotes MMP-9-mediated metastasis by
simultaneously suppressing PDCD4 and PTEN in laryngeal
squamous cell carcinoma
Author(s) Li, Z; Gao, W; Lei, WB; Zhao, J; Chan, YW; Wei, WI; Ho, WK;Wong, TS
Citation Oncotarget, 2016, v. 7 n. 36, p. 58218-58233
Issued Date 2016
URL http://hdl.handle.net/10722/243831
Rights This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Oncotarget58218www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 36
INTRODUCTION
Cancer of the larynx originating from the head 
and neck region is the second most common upper-
aerodigestive cancer [1, 2]. Histologically, laryngeal 
squamous cell carcinoma (LSCC) is the major form. 
Despite the advances of cancer treatment in the past few 
decades, the prognosis of LSCC patients remains poor 
without significant improvement [3]. Recent data reveals 
that the morbidity and mortality associates with LSCC 
are increasing in recent year [3, 4]. Local invasion and 
metastatic spread of cancer cells is one of the main causes 
of death in LSCC patients [5]. Laryngeal cancer patients 
present with cervical lymph node involvement have poorer 
disease free interval and overall survival [6]. Given that the 
key cellular and molecular mechanisms resulting in LSCC 
migration and invasion are less understood, investigation 
on the underlying mechanism will be clinically beneficial 
for developing molecular targeting therapy.
MicroRNAs are highly conserved non-coding RNAs 
(~18–25 nucleotides) involved in gene regulation at post-
transcription level. The single-stranded mature microRNA 
can bind to the target mRNA at the 3′ untranslated region 
(3′UTR) forming a stable duplex by Watson-Crick 
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ABSTRACT
MicroRNA controls cancer invasion by governing the expression of gene 
regulating migration and invasion. Here, we reported a novel regulatory pathway 
controlled by miR-744-3p, which enhanced expression of matrix metallopeptidase 9 
(MMP-9) in laryngeal squamous cell carcinoma (LSCC). We profiled the differential 
micoRNA expression pattern in LSCC cell lines and normal epithelial cultures derived 
from the head and neck mucosa using microRNA microarray. MiR-7-1-3p, miR-196a/b 
and miR-744-3p were expressed differentially in the LSCC cell lines. Subsequent 
validation using real-time PCR revealed that high miR-744-3p level was positively 
correlated with regional lymph node metastasis of LSCC. Real-time cellular kinetic 
analysis showed that suppressing miR-744-3p could inhibit migration and invasion 
of LSCC cell lines and reduce the number of lung metastatic nodules in nude mice 
modules. In silico analysis revealed that miR-744-3p targeted 2 distinct signaling 
cascades which eventually upregulated MMP-9 expression in LSCC. First, miR-744-3p 
could suppress programmed cell death 4 (PDCD4), a direct suppressor of NF-кB (p65). 
PDCD4 could also prevent AKT activation and suppress MMP-9 expression. Further, 
suppressing miR-744-3p expression could restore phosphatase and tensin homolog 
(PTEN) expression. PTEN could inhibit AKT activation and inhibit MMP-9 expression 
in LSCC cells. The results revealed that suppressing miR-744-3p was effective to 
inhibit LSCC metastasis by inactivating AKT/mTOR and NF-кB (p65) signaling cascade. 
Targeting miR-744-3p could be a valuable therapeutic intervention to suppress the 
aggressiveness of LSCC.
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complementarities at a partial complementary manner. 
By recruiting and incorporating with the RNA-induced 
silencing complex (RISC), translation of the target mRNA 
transcript is hindered and/or the mRNA is subjected to 
degradation [7, 8]. MicroRNA is recognized as a master 
gene regulator as individual microRNA could target a 
plethora of mRNA transcript at multiple sites the same 
time [9]. This multiple target feature makes microRNA 
an efficient effector in target-based cancer therapy 
which offers unique advantages as compared with the 
conventional treatment modalities [10]. 
In order to identify the key functional microRNA in 
LSCC, we performed microRNA profiling in LSCC cell 
lines using microRNA microarray and validated the results 
in LSCC tissues. We found that deregulation of miR-744- 3p 
was a common event in LSCC. At present, however, its 
functions in LSCC remains to be defined. In silico analysis 
showed that miR-744-3p could directly target the mRNA 
transcript of both programmed cell death 4 (PDCD4) and 
phosphatase and tensin homolog (PTEN), both of which 
had been reported to be correlated with LSCC metastasis 
[11–13]. Reduced PDCD4 was usually found in aggressive 
head and neck cancers [14]. PDCD4 knock-out mice 
showed high systematic dissemination rate implying the 
functional implication in the metastatic process [15, 16]; 
PTEN, on the other hand, was a well-known anti-neoplastic 
factor [17], which antagonized the action of PI3K by 
converting PIP3 to PIP2 via dephosphorylation [18]. 
Both PTEN and PDCD4 were identified as the upstream 
suppressors of matrix metallopeptidase 9 (MMP-9) which 
facilitated cancer cell migration through degrading the 
collagenous substrates in the surrounding extracellular 
matrix [19]. Our results revealed a novel pathway employed 
by LSCC in promoting LSCC migration and metastasis by 
overexpressing miR-744-3p.  
RESULTS
MicroRNA expression patterns in the LSCC and 
normal epithelial cell lines
Table 1 showed the deregulated microRNA 
expression profile in LSCC cell lines. MiR-7-1-3p, 
miR- 196a, miR-196b and miR-744-3p were detected in 
LSCC but not normal epithelial cultures. In comparison, 
let-7a-3p, miR-34a-3p, miR-338-5p and miR-365a- 5p 
could only be detected in normal epithelial culture. 
Twenty-three microRNAs showed significant difference 
in expression level between the LSCC and normal cell 
lines (1.5-fold, P < 0.05) (Figure 1). The microarray data 
are publicly available at GEO (Accession No. GSE73171).
MiR-744-3p was overexpressed in LSCC tissues
Next, we validated the microarray results by analyzing 
the aberrant expressed microRNA level (miR-7-1-3p, 
miR- 196a, miR-196b, miR-744-3p, let-7a-3p, miR-34a- 3p, 
miR-338-5p and miR-365a-5p) in a cohort of 47 LSCC 
tissues using QPCR and compared with the paired normal 
tissues (Figure 1). 
Three microRNA (miR-196a, miR-196b and 
miR- 744-3p) were significantly upregulated in the 
LSCC tissue (P < 0.05). Let-7a-3p was not detected in 
all the LSCC tissues and the paired normal epithelia. 
MiR- 7-1-3p, miR-338-5p and miR-365a-5p were 
detected in the LSCC tissues and the paired normal 
epithelia. However, there were no significant difference 
in the expression level between cancer and the normal 
tissues (P > 0.05). In the microarray results, miR-34a-3p 
expression was found in normal epithelial cell lines and 
was undetectable in the LSCC cell lines. In the validation 
set using laryngeal tissues, however, miR-34a-3p was 
significantly upregulated in tumor (P = 0.013). Thus, 
we shortlisted miR-196a, miR-196b and miR-744- 3p 
as candidate microRNA and explored their clinical 
significance by evaluating the statistical association with 
the clinicopathological parameters of LSCC patients. 
All the LSCC cases were grouped into high 
expression and low expression group using median 
expression level of each microRNA in LSCC as cut- off 
points. As shown in Table 2, expression levels of 
miR- 196a and miR-196b were not statistically associated 
with the age, smoking habit, drinking habit, T-stage, 
regional lymph node status, or clinical stage of our LSCC 
patients. In contrast, high miR-744-3p expression was 
significantly associated with the cervical lymph node 
metastasis in LSCC (P = 0.007). Thus, we proposed that 
miR-744-3p overexpression could promote migration and 
invasion of the LSCC cells.
Suppressing miR-744-3p reduced the metastatic 
ability of LSCC
To explore the functional impact of miR-744-3p 
overexpression on LSCC migration and invasion, we 
monitored the dynamic changes of migration and invasion 
capacities of LSCC cell lines (SNU899 and SNU1076) 
expressing the miR-744-3p shRNA. Significant reduction 
in migration and invasion ability was observed in both 
SNU899 and SNU1076 (Figure 2F). To confirm the 
in vitro data, the miR-744-3p suppressed LSCC cell line 
was injected into nude mice and the formation of lung 
metastatic foci were evaluated on day 60 after injection. 
Mice injected with miR-744-3p suppressed LSCC cells 
group had lower number of metastatic cancer nodules in 
comparison with the control group (Figure 2G–2J). 
In silico analysis showed that miR-744-3p 
targeted PDCD4 and PTEN simultaneously
To evaluate the functional target of miR-744- 3p, the 
target transcript was predicted using miRWalk. In total, 
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2004 genes were simultaneously predicted by 2 or more 
databases.  Of which, 13 genes had been reported to be 
downregulated in LSCC tissues [20–28]. Next, we used the 
mirSVR score to narrow down the gene list. Six transcripts 
(PDCD4, PTEN, SCN2B, IGFBP5, GPR64, BOC) 
had mirSVR score < –0.01 suggesting that they could 
potentially form thermodynamically stable complexes with 
the mature miR-744-3p (Table 3). Among the 6 genes, only 
PDCD4 and PTEN were reported to consistently suppress 
head and neck cancer cell metastasis in previous studies. 
PTEN restoration could significantly suppress migration 
and invasion in LSCC and oral carcinoma. On the other 
hand, low PDCD4 expression was significantly related 
with lymph node metastasis in head and neck malignancy, 
and PDCD4 upregulation could inhibit invasiveness of oral 
cancer and nasopharyngeal carcinoma cells [29–34]. 
Table 1: Expression of deregulated microRNAs in LSCC cell lines and normal epithelial culture 
revealed by microarray profiling
ProbeSet Name Detectable in tumor cell lines
Detectable in normal 
epithelial culture Mean Ratio (T/N) P value (T test)
hsa-let-7a-3p No Yes ----- -----
hsa-miR-338-5p No Yes ----- -----
hsa-miR-34a-3p No Yes ----- -----
hsa-miR-365a-5p No Yes ----- -----
hsa-miR-193a-5p Yes Yes 0.1724 0.03559
hsa-miR-99a Yes Yes 0.2983 0.02728
hsa-miR-4306 Yes Yes 1.5112 0.04447
hsa-miR-181d Yes Yes 1.5870 0.00419
hsa-miR-23b-5p Yes Yes 1.6129 0.03223
hsa-let-7d Yes Yes 1.6737 0.01306
hsa-miR-574-5p Yes Yes 1.7924 0.01606
hsa-miR-93 Yes Yes 1.7939 0.01544
hsa-miR-151-3p Yes Yes 1.8870 0.00048
hsa-miR-301a Yes Yes 1.889 0.03815
hsa-miR-106b Yes Yes 1.9559 0.00079
hsa-miR-16 Yes Yes 2.1452 0.01156
hsa-miR-151-5p Yes Yes 2.2301 0.00450
hsa-miR-339-3p Yes Yes 2.2357 0.00998
hsa-miR-25 Yes Yes 2.2572 0.01428
hsa-miR-93-3p Yes Yes 2.3123 0.00004
hsa-miR-877 Yes Yes 2.3139 0.01860
hsa-miR-27b-5p Yes Yes 2.3741 0.00401
hsa-miR-106b-3p Yes Yes 2.6147 0.00230
hsa-miR-339-5p Yes Yes 2.6273 0.00340
hsa-miR-30a Yes Yes 3.2300 0.00383
hsa-miR-625 Yes Yes 5.1155 0.04386
hsa-miR-196a Yes No ----- -----
hsa-miR-196b Yes No ----- -----
hsa-miR-7-1-3p Yes No ----- -----
hsa-miR-744-3p Yes No ----- -----
Twenty-three microRNAs showed significant difference in expression level between the LSCC and normal cell lines 
(1.5– fold, P < 0.05). MiR-7-1-3p, miR-196a, miR-196b and miR-744-3p were detected in LSCC but not normal epithelial 
cultures. In comparison, let-7a-3p, miR-34a-3p, miR-338-5p and miR-365a-5p could only be detected in normal epithelial 
culture.
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Figure 1: Deregulated microRNAs in LSCC. As shown in the heat map, 21 microRNAs overexpressed and 2 microRNAs were 
downregulated in LSCC cell lines respectively. The line charts showed the expression levels of the 8 differentially expressed microRNAs 
in LSCC tissues. MiR-196a, miR-196b and miR-744-3p were significantly overexpressed in LSCC compared with their paired normal 
counterparts (P < 0.05). 
Table 2: Clinical findings and expression of miR-196a, miR-196b and miR-744-3p in LSCC
miR-196a miR-196b miR-744-3p
Total High level Low level P value High level Low level P value High level Low level P value
Total 47 24 23 24 23 24 23
Age
≥ 60 24 13 11 0.664 14 10 0.308 14 10 0.308
< 60 23 11 12 10 13 10 13
Smoking
Yes 36 20 16 0.265 21 15 0.071 18 18 0.792
No 11 4 7 3 8 6 5
Alcohol consumption
Yes 17 10 7 0.423 11 6 0.159 10 7 0.423
No 30 14 16 13 17 14 16
T stage
T1/T2 17 9 8 0.846 10 7 0.423 8 9 0.679
T3/T4 30 15 15 14 16 16 14
Lymph node metastasis
Yes 15 9 6 0.401 7 8 0.68 12 3 0.007
No 32 15 17 17 15 12 20
Clinical stage
I + II 12 5 7 0.45 7 5 0.559 4 8 0.154
III + IV 35 19 16 17 18 20 15
Using the median of individual microRNA expression level as cut-off point, the LSCC cases were allocated into high level and 
low level groups regarding the corresponding microRNA expression level. Pearson Chi square test was adopted to examine 
the correlation between the clinical feature and each microRNA expression level. The high miR-744-3p expression level could 
significantly increase the risk of lymph node metastasis in LSCC. 
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Reduced PDCD4 and PTEN expression were 
correlated with the regional nodal status of 
LSCC patients
In the LSCC tissues, PDCD4 and PTEN expression 
were significantly reduced (Figure 3A). Low PDCD4 
(P = 0.037) and PTEN (P < 0.001) were significantly 
associated with the regional lymph node metastasis of 
LSCC patients. Reduced PTEN expression was also 
found to be significantly associated with the advanced 
clinical stage (P = 0.036). Furthermore, MiR-744-3p was 
negatively correlated with PTEN (R = –0.319, P = 0.029) 
and PDCD4 (R = –0.574, P < 0.001) in LSCC tissues 
(Table 4). 
MiR-744-3p targeted PDCD4 and PTEN 
transcript in LSCC 
As shown in Figure 3B, suppressing miR-744-3p 
in the LSCC cell lines (SNU899 and SNU1076) resulted 
in significant increase in PTEN and PDCD4 transcript 
expression (P < 0.05). Target gene prediction analysis 
revealed that PDCD4 and PTEN 3′-UTR harbored the 
binding sites for miR-744-3p seed sequence. In the 
Ago2-IP/IgG-IP, PDCD4 and PTEN mRNA levels were 
reduced when the endogenous expression of miR-744-3p 
were suppressed by shRNA (Figure 3C). The association 
between miR-744-3p and PDCD4 or PTEN was further 
validated using luciferase activity reporter containing 
PDCD4 or PTEN 3′-UTR. As shown in Figure 3D and 3E, 
there was a significant increase in the luciferase activity 
when miR-744-3p was suppressed endogenously. In the 
mutant construct of which miR-744-3p binding sequence 
on the PDCD4 or PTEN 3′-UTR were disrupted, the 
luciferase activity remained stable with no significant 
changes.  
Suppression of miR-744-3p reduced AKT and 
NF-κB (p65) activation through PTEN and 
PDCD4 enhancement in LSCC 
In SNU899 and SNU1076 with miR-744-3p 
suppression, the levels of PTEN and PDCD4 proteins 
were significantly increased, while phosphorylated AKT 
and phosphorylated NF-κB (p65) protein levels were 
significantly reduced. The phosphorylated IKKα/β and 
IκB-α level remained unchanged in the miR-744-3p 
suppressed LSCC cell lines (Figure 4A). 
Figure 2: Influence of miR-744-3p suppression on LSCC metastasis. (A–D) Figures of LSCC cell lines with mock control 
vector or expressing miR-744-3p shRNA. The left part of each figure is the bright field image of each clone, while the right part is the green 
fluorescent image of cells. (A) SNU899 with mock control vector; (B) SNU899 stably expressing miR-744-3p shRNA; (C) SNU1076 with 
mock control vector; (D) SNU1076 stably expressing miR-744-3p shRNA. (E) Relative expression levels of miR-744-3p. Compared with 
the mock control, the stable LSCC clone compromising miR-744-3p shRNA exhibited significant reduction of miR-744-3p expression level. 
(F) Real-time measurement of LSCC cell migration and invasion. The reduction of miR-744-3p could significantly inhibit the LSCC cell 
migration and invasion. (G– J) Metastatic foci in lung of representative nude mice injected with miR-744-3p suppressing LSCC cell lines and 
mock control (H&E staining). G: SNU899 with mock control vector; (H) SNU899 stably expressing miR-744-3p shRNA; (I) SNU1076 with 
mock control vector; (J) SNU1076 stably expressing miR-744-3p shRNA. Compared with the mock control groups, less metastatic foci were 
observed in the mice injected with miR-744-3p silencing LSCC cells. White arrow: metastatic foci. *P < 0.05, **P < 0.01.
Oncotarget58223www.impactjournals.com/oncotarget
MMP-9 expression was reduced in miR-744-3p 
silencing LSCC
MMP-9 expression was significantly upregulated 
in the LSCC tissues (P < 0.001, Figure 4B). High MMP-9 
expression was significantly associated with the regional 
lymph node metastasis of LSCC patients (P = 0.011, Table 4). 
As activated AKT and NF-κB (p65) could promote 
MMP-9 upregulation in head and neck cancers, we 
hypothesized that the miR-744-3p modulated MMP- 9 
expression in LSCC. As shown in Figure 4C and 4D, 
MMP- 9 mRNA and protein level were remarkably 
reduced in miR-744-3p suppressed SNU899 and SNU1076 
(P < 0.05). 
PDCD4 restoration reduced the metastatic 
ability of LSCC 
As a famous tumor suppressor gene, PDCD4 
was described as inhibitor of cancer cell migration 
and metastasis in different cancer forms including 
LSCC. Low PDCD4 expression was observed to be 
significantly related with poor differentiation and lymph 
node metastasis in LSCC patients [12, 13]. However, 
the mechanisms underlying its suppression remained to 
be determined. We continuously monitored the dynamic 
changes of migration and invasion capacities of LSCC cell 
lines with PDCD4 restoration. LSCC cell lines (SNU899 
and SNU1076) expressing PDCD4 (Figure 5A and 5B) 
Table 3: Genes consistently suggested as potential targets of miR-744-3p and downregulated 
transcripts in LSCC
Gene Sequence Dataset mirSVR score
AKT2 DIANAmT , miRanda –0.0005
EMP1 miRanda, miRWalk –0.0057
ADH1B miRanda, miRWalk –0.0063
ADH1C miRanda, miRWalk –0.0162
MS4A1 miRanda, miRWalk –0.0187
CLDN10 miRanda, miRWalk –0.0491
ATOH8 miRanda, miRWalk –0.0993
PDCD4 miRanda, miRWalk –0.2355
PTEN miRanda, miRWalk –0.3082
SCN2B miRanda, miRWalk –0.3613
IGFBP5 miRanda, miRWalk –0.4013
GPR64 miRanda, miRWalk –0.4579
BOC miRanda, miRWalk –1.1002
In total 13 potential target genes of miR-744-3p were retrieved, which were also downregulated in LSCC according to 
literature review.
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showed significant reduction in the migration and invasion 
ability in comparison with the mock controls (Figure 5C). 
PDCD4 restoration reduced AKT and NF-κB p65 
activation as well as MMP-9 expression in LSCC 
In the PDCD4 overexpressing clones, 
phosphorylated AKT and phosphorylated NF-κB 
(p65) levels were significantly reduced, while PDCD4 
protein level was significantly increased (Figure 5E). 
The phosphorylated IKKα/β and IκB-α level remained 
unchanged in the LSCC cell lines with high PDCD4 
expression (Figure 5E). Moreover, MMP-9 mRNA and 
protein level were remarkably reduced in SNU899 and 
SNU1076 with PDCD4 restoration (Figure 5D and 5E). 
MiR-744-3p shRNA showed higher efficacy than 
everolimus in suppressing MMP-9 expression in 
LSCC 
Everolimus is an mTOR inhibitor. Exposing LSCC 
to everolimus will lead to a reduction of the downstream 
gene regulated by mTOR signaling cascade. LSCC 
exposed to everolimus showed reduction in MMP-9 
expression (Figure 6). MiR-744-3p shRNA, however, 
showed higher efficacy than everolimus in suppressing 
MMP-9 expression in LSCC (Figure 6). Compared with 
the mock control, MMP-9 mRNA level significantly 
decreased to 40% and 15% in SNU899 and SNU1076 
when miR-744-3p shRNA were expressed in the LSCC 
cell lines (P < 0.05). 
Figure 3: Expression of PTEN and PDCD4 transcripts and their interaction with miR-744-3p in LSCC. (A) Relative 
expression levels of PTEN mRNA and PDCD4 mRNA in LSCC. Compared with the normal epithelial counterparts, the tumor exhibited 
significantly lower PTEN mRNA and PDCD4 mRNA expression levels. (B) Relative expression levels of PTEN mRNA and PDCD4 mRNA 
in LSCC cell lines. By miR-744-3p suppression, expression levels of PTEN and PDCD4 were significantly increased in both of SNU899 
and SNU1076. (C) Ago 2 protein immunoprecipitation. Compared with mock control group, the suppression of miR-744- 3p significantly 
reduced miR-744-3p, PTEN and PDCD4 binding to the Ago2 protein. (D, E) Relative luminenscent signal intensity in luciferase reporter 
assay. The suppression of miR-744-3p significantly enhanced luciferase expression from the reporter plasmid containing the wild- type 
PTEN 3′-UTR sequence or containing the wild- type PDCD4 3′-UTR sequence. Similar enhancement of luminenscent signal intensity 
due to miR-744-3p suppression was not observed in the groups with mutant PTEN 3′-UTR sequence or mutant PDCD4 3′-UTR sequence. 
*P < 0.05, **P < 0.01.
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DISCUSSION
As there was currently no data on the pathological 
functions of miR-744-3p, we first examined the tissue 
expression level and evaluated the statistical association 
with the clinicopathological characteristics of our LSCC 
patients. The association between high miR-744-3p 
expression and regional lymph node positive suggested 
that miR-744-3p could possibly play a part in controlling 
LSCC migration and invasion. To establish the causal 
relationship, we established the miR-744-3p suppressed 
LSCC cell lines and measured the changes in migration 
and invasion property of LSCC cells using real-time 
cellular kinetic assays and animal models. Our results 
confirmed that the expression level of miR-744-3p could 
have a functional impact on the migration and invasion 
propensity of LSCC cells. 
MMP-9 expression is regulated by the upstream 
regulator PDCD4 and PTEN. MMP-9 could shape the 
development of epithelial–mesenchymal transition (EMT) 
phenotype in LSCC [35, 36]. Further, LSCC patients with 
low MMP-9 expression had a better 5-year survival rate 
[37]. In our LSCC samples, both PDCD4 and PTEN were 
significantly reduced. As miR-744-3p expression level 
in LSCC tissue was negatively correlated to the PDCD4 
and PTEN transcript levels in the same tissue cohort, 
Table 4: Correlation between PTEN, PDCD4 mRNA expression and clinical characteristics of 














Total 23 24 23 24 24 23
Age
≥ 60 9 15 0.109 8 16 0.029 14 10 0.387
< 60 14 9 15 8 10 13
Smoking
Yes 20 16 0.101 18 18 0.792 17 19 0.494
No 3 8 5 6 7 4
Alcohol consumption
Yes 7 10 0.423 13 11 0.159 6 11 0.135
No 16 14 17 6 18 12
T stage
T1/T2 9 8 0.679 10 7 0.307 10 7 0.547
T3/T4 14 16 13 17 14 16
Lymph node metastasis
Yes 4 11 0.037 1 14 < 0.001 12 3 0.011
No 19 13 22 10 12 20
Clinical stage
I + II 8 4 0.154 9 3 0.036 5 7 0.517
III + IV 15 20 14 21 19 16
Correlation with miR-744-3p (Pearson correlation) 
High miR-744-3p 
expression level 5 19 R = –0.574 8 16 R = –0.319 14 10 R = 0.149
Low miR-744-3p 
expression level 18 5 P < 0.001 15 8 P = 0.029 10 13 P = 0.387
Using the median expression level of PTEN, PDCD4 and MMP-9 mRNA in LSCC tissues as cut-off value, the patients were 
divided into high expression level group and low expression level group. Low PTEN expression in LSCC was significantly 
correlated with lymph node metastasis and late clinical stage. Low PDCD4 expression in LSCC was significantly correlated 
with lymph node metastasis. High MMP-9 expression in LSCC was significantly correlated with lymph node metastasis. 
Furthermore, the expression level of PTEN and PDCD4 were negatively correlated with miR-744-3p expression level.
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Figure 4: Expression alteration of PTEN, PDCD4, phosphorylated AKT, phosphorylated NF-кB and MMP-9 caused by 
miR-744-3p suppression in LSCC. (A) Western blot analysis on protein expression in LSCC cell lines. By miR-744-3p suppression, 
PTEN and PDCD4 protein levels were significantly increased, while phosphorylated AKT and phosphorylated NF-кB protein levels were 
significantly reduced. (B) Relative expression levels of MMP-9 mRNA in LSCC. Compared with the normal epithelial counterparts, the tumor 
exhibited significantly higher MMP-9 mRNA expression level. (C) Relative expression levels of MMP-9 mRNA in LSCC cell lines. By 
miR-744-3p suppression, MMP-9 mRNA expression level was significantly reduced in both of SNU899 and SNU1076. (D) MMP-9 protein 
expression levels in LSCC cell lines. By miR-744-3p suppression, MMP-9 protein level was significantly reduced. *P < 0.05, **P < 0.01.
Figure 5: Influence of PDCD4 restoration on LSCC. (A) SNU899 stably expressing PDCD4; (B) SNU1076 stably expressing 
PDCD4. The upper part of figure is the bright field image of each clone, while the lower part is the green fluorescent image of cells. (C) Real-
time measurement of LSCC cell migration and invasion. PDCD4 restoration could inhibit LSCC cell migration and invasion. (D) Relative 
expression levels of PDCD4 and MMP-9 mRNA in LSCC cell lines. Compared with the mock control, the stable LSCC clone with PDCD4 
restoration exhibited significant enhancement of PDCD4 and reduction of MMP-9 mRNA expression levels. (E) Protein expression levels 
of PDCD4, phosphorylated AKT, phosphorylated NF-кβ and MMP-9 in LSCC cell lines. Compared with the mock control, PDCD4 protein 
level was significantly increased, while phosphorylated AKT, phosphorylated NF-кβ and MMP-9 protein levels were significantly reduced. 
Oncotarget58227www.impactjournals.com/oncotarget
we proposed that miR-744-3p could possibly function 
as MMP-9 enhancer by inhibiting PDCD4 and PTEN 
expression in LSCC. 
Our data showed that decreased PDCD4 was 
associated with the nodal status of LSCC patients 
indicating the role in LSCC migration and invasion. 
PDCD4 could suppress MMP-9 expression by inactivating 
AKT/mTOR signaling or reducing NF-кB (p65) activation 
[38, 39]. In the PDCD4 overexpressing LSCC cell lines, 
we noticed that the signal intensity of both pathways was 
reduced significantly. NF-кB (p65) was a critical oncogenic 
transcription factor. Activated NF-кB (p65) was involved 
in promoting cancer cell survival, inhibiting the apoptotic 
machinery, promoting angiogenesis and inducing cancer 
invasion [40]. PDCD4 could inactivate NF-кB (p65) and 
prevent NF-кB (p65)-mediated transcription activation of 
MMP-9 [41]. Hence, suppressing PDCD4 could promote 
cancer migration and invasion. PDCD4 could inactivate 
nuclear NF-κB (p65) without interfering the activation 
status of upstream IKKα/β and IκBα in brain tumor [41]. 
This was because PDCD4 could interact with NF-κB 
(p65) physically. Our data illustrated that the NF- κB (p65) 
inhibitory property of PDCD4 was effectively abolished 
by the high expression of miR-744-3p in LSCC. 
The phosphatidylinositol 3 kinase (PI3K) / protein 
kinase B (PKB, also known as AKT) and mammalian 
target of rapamycin (mTOR) signaling cascade is the 
most commonly altered signaling cascade in head and 
neck carcinoma. PI3K (class I, II, and III) is a family of 
intracellular lipid and serine/threonine kinases. It functions 
by phosphorylating the downstream phosphatidylinositols 
and phosphoinositides at the 3′-hydroxyl group which 
triggers a cascade of signaling event. Upon receiving 
external stimulus, PI3K is recruited to the plasma 
membrane by the activated receptor and catalyzes the 
formation of phosphatidylinositol 3, 4, 5- bisphosphate 
(PIP3) from phosphatidylinositol 4, 5- bisphosphate 
(PIP2). PIP3 will activate the serine/threonine protein 
kinase Akt (Akt1, Akt2, and Akt3) and activate its activity 
by phosphorylating threonine 308 (by 3-phosphoinositide 
dependent kinase) or serine 473 (by rapamycin-insensitive 
mTOR complex/mTORC2) after binding AKT with its 
PH domain [18, 42, 43]. AKT and mTOR control key 
oncogenic signaling molecule including TP53, mitogen-
activated protein kinase (MAPK)/ extracellular signal-
regulated kinase, and eukaryotic initiation factor 4E 
(eIF4E) as well as NF-κB (p65) [44]. Phosphorylated 
AKT activates mTOR complex 1 (mTORC1), which 
later releases eIF4E by phosphorylation of eIF4E-binding 
protein (4EBP1). It has been shown that free eIF4E 
could activate MMP-9 expression [45]. In this signaling 
cascade, the tyrosine phosphatase PTEN functions as a 
central negative regulator which antagonize the action of 
PI3K by converting PIP3 to PIP2 via dephosphorylation 
[18] and hence reducing the quantity of activated AKT 
in the cells [46, 47]. It had been reported that reduced 
PTEN expression was associated with the deep invasion 
and lymph nodes metastasis of LSCC [11]. Low PTEN 
was observed in precancerous lesions suggesting that 
loss of PTEN was an early event in the development 
process of LSCC [27]. Targeting the PI3K/AKT/mTOR 
signaling pathway in head and neck cancer was suggested 
to be promising in improving the treatment efficacy and 
clinical outcome [48, 49]. Here, our results suggested that 
miR-744-3p could possibly control the mTOR signaling 
cascade by inhibiting PTEN expression in LSCC. 
Everolimus is a selective inhibitor of mTOR 
approved by FDA for use in cancer treatment. As 
miR- 744- 3p could simultaneously target dual signaling 
channels responsible for MMP-9 activation, we 
Figure 6: MMP-9 expression in LSCC cell lines. Significant downregulation of MMP-9 mRNA expression level was observed 
in LSCC cell lines with miR-744-3p suppression. However, the reduction of MMP-9 mRNA was not significant in LSCC cell lines after 
administration of everolimus. *P < 0.05, **P < 0.01.
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hypothesized that suppressing miR-744-3p could have 
a therapeutic impact on inhibiting MMP-9 expression 
and should have a better efficacy than everolimus. In 
comparison with everolimus, MMP-9 expression was 
significantly reduced in miR-744-3p suppressed LSCC cell 
lines indicating that targeting miR-744-3p had a therapeutic 
impact in preventing MMP-9 upregulation in LSCC.
Collectively, our data suggested that miR-744-3p 
was an oncogenic microRNA in LSCC. On one hand, 
miR-744-3p suppressed the mTOR upstream regulatory 
element PTEN in the PI3K/AKT/mTOR regulatory axis, 
which controlled MMP-9 transcription. On the other hand, 
miR-744-3p activated another MMP-9 regulatory axis by 
provoking the signaling cascade controlled by NF-κB p65 
via PDCD4 suppression (Figure 7). High miR-744-3p was 
crucial to activate MMP-9 expression in LSCC. 
MATERIALS AND METHODS
Cell cultures and drug
LSCC cell lines (SNU46, SNU899, and SNU1076) 
were obtained from Korean Cell Line Bank [50]. Normal 
epithelial cultures derived from oral cavity epithelia 
(HOK1 and HOK2) and tonsil epithelia (HTEpiC) were 
obtained from ScienCell Research Laboratories. The 
LSCC cell lines were maintained in RPMI 1640 medium 
supplemented with 10% FBS, 200 units/ml penicillin G 
sodium, 200 μg/ml streptomycin sulfate and 0.5 μg/ ml 
amphotericin B. HOK1 and HOK2 were maintained 
in oral keratinocyte medium (ScienCell Research 
Laboratories) together with oral keratinocyte growth 
supplement (ScienCell Research Laboratories). HTEpiC 
was maintained in tonsil epithelial cell medium (ScienCell 
Research Laboratories) supplemented with tonsil epithelial 
growth supplement (ScienCell Research Laboratories). 
Everolimus were obtained from Sigma-Aldrich. 
Tissue samples
Forty-one paired LSCC and the corresponding 
normal epithelia were obtained from the First Affiliated 
Hospital, Sun Yat-sen University, Guangdong, China. Six 
paired LSCC tissues were obtained from Department of 
Surgery, Queen Mary Hospital, The University of Hong 
Kong. Consent of tissue donation for research purpose 
was obtained before tissue collection. Tissues were 
collected from patients with no prior treatment including 
radiotherapy and/ or chemotherapy. All the tissues were 
snap-frozen in liquid nitrogen and were stored at –80℃ 
until use. The protocol was approved by the human 
research ethics committee of Sun Yet-sen University 
(reference number: 2013_23) and University of Hong 
Kong (reference number: UW 10-142). 
Figure 7: Illustration of potential pathways for miR-744-3p mediating metastasis in LSCC. MiR-744-3p promotes LSCC 
metastasis by simultaneously inhibiting PTEN and PDCD4. Both of PTEN suppression and PDCD4 suppression can activate AKT and 
mTOR, and then further promote transcription activation of MMP-9, resulting in enhancement of LSCC metastasis. Moreover, loss of 
PDCD4 leads to NF-κB (p65) activation, which also promotes MMP-9 expression. Hence, suppression of miR-744-3p can powerfully 
prevent LSCC metastasis by inhibiting MMP-9 through inactivation of those 2 pathways above.
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MicroRNA microarray
RNA quality was evaluated using Agilent 2100 
bioanalyser (Agilent Technologies) prior to microarray 
experiment. All the samples had rRNA Ratio (28s/18s) 
over 1.8 and RNA Integrity Number (RIN) over 8.0 
(Figure 8). The experiments were performed in the 
Centre for Genomic Sciences, The University of Hong 
Kong. Data were analyzed by miRNA QC Tool software 
(Affymetrix). MicroRNA with P < 0.05 and 1.5-fold 
difference were considered as deregulated microRNA in 
LSCC. 
Quantitative reverse transcription polymerase 
chain reaction (QPCR)
Total RNA from the cell lines and tissues 
were extracted with TRIZOL reagent (Invitrogen). 
For microRNA cDNA preparation, microRNA was 
polyadenylated by using the Poly (A) Polymerase Tailing 
Kit (Illumina). The cDNA product was then generated 
using High-Capacity cDNA reverse transcription 
kit (Invitrogen) following the methods described 
by Reichenstein et al. [51]. For conventional cDNA 
conversion, mRNA was reversely transcribed into cDNA 
using High Capacity cDNA Reverse Transcription Kit 
(Invitrogen). Real-time PCR were performed using 
FastStart Universal Probe Master (Roche Applied Science) 
on LightCycler® 480 (Roche Applied Science). Reaction 
was performed at 95°C for 10 minutes followed by 
45 cycles of 95°C for 15 seconds and 60°C for 1 minute. 
Table 5 listed all the primers and the probes used in this 
study. 
Generation of stable LSCC clone expressing 
miR-744-3p shRNA or PDCD4
A stem-loop shRNA with imperfect complementation 
was constructed according to the antisense miR-744-3p 
sequence (5′-GACAACGGTGATTGGAGTTGGA-3′). 
The miR-744-3p shRNA coding sequence was cloned 
into lentivector pGreenPuro (System Biosciences) to 
generate the miR-744-3p shRNA expressing vector 
(pGreenPuro-miR-744-shRNA vector). PDCD4 insert for 
construction of stable LSCC clone expressing PDCD4 
was amplified using Roche FastStart High Fidelity 
Figure 8: The RNA quality of the cell lines for microRNA microarray profiling. All the samples had rRNA Ratio (28s/18s) 
over 1.8 and RNA Integrity Number (RIN) over 8.0.
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PCR System (Roche Applied Science). The forward 
primer for PDCD4 insert amplification was: 5′- GCA 
TAATGGATGTAGAAAATGAGCA-3′, and the reverse 
primer was: 5′- CGTACTCAGTAGCTCTCTGGTTTAA -3′. 
The PDCD4 coding sequence was cloned into lentivector 
pCDH-CMV-MCS-EF1-copGFP (System Biosciences) 
generating the pCDH-PDCD4 vector. The pGreenPuro-
miR-744-shRNA or pCDH-PDCD4 vector as well as their 
mock vectors was further packaged into lentiviral particles 
by 293-FT cells (Life technologies) using the Lenti Starter 
Kit (System Biosciences). Subsequently, the lentiviral 
particles were transduced into the LSCC cell lines SNU899 
and SNU1076 by TransDux™ (System Biosciences). 
Real-time migration and invasion assays
xCELLigence Real-Time Cell Analyzer (Roche 
Applied Science) was used to measure the changes in 
migration and invasion ability of LSCC cells in response 
to the changes in miR-744-3p or PDCD4 levels. CIM-
Plate 16 was adopted for the migration and invasion 
assay. The dynamic changes of cell number (expressed 
as cell migration index) from upper chamber (coated 
with fibronectin) to lower chamber due to the migratory 
capacitance of LSCC cells were measured continuously 
over 24 hours. For the measurement of invasion 
propensity, the upper chamber of CIM-Plate 16 was coated 
with Matrigel (1:30 dilution; BD Biosciences) for 4 hour 
at 37°C before cell seeding. Subsequently, the dynamic 
invasion of LSCC cells through the Matrigel layer was 
recorded and expressed as cell invasion index. 
In silico microRNA target gene prediction
MiRWalk (http://www.umm.uni-heidelberg.de/
apps/zmf/mirwalk/) was used to predict the candidate 
transcripts which are targeted by miR-744-3p [52]. 
MiRWalk retrieves predicted target gene lists from 
12 databases (DIANA-microTv4.0, DIANA-microT-
CDS, miRanda-rel2010, mirBridge, miRDB4.0, miRmap, 
miRNAMap, PicTar2, PITA, RNA22v2, RNAhybrid2.1 
and Targetscan6.2). Mature miR-744-3p sequence, 
MIMAT0004946 was used in the computational analysis. 
Genes simultaneously reported by 2 or above databases 
were selected. In addition, gene list was generated from 
literature. Genes reported to be downregulated in LSCC 
were selected and generate the second gene list. The 
common genes in the 2 gene lists were further filtered 
using the machine learning regression method mirSVR 
scoring method, which measures the likelihood of target 
mRNA down-regulation by the microRNA from sequence 
and structure features in microRNA/mRNA predicted 
target sites [53]. A lower mirSVR score implies a greater 
likelihood of the downregulation of potential target genes 
due to specific microRNA. Gene with a mirSVR score less 
than –0.01 was selected for subsequent validation.
Western blot analysis
Western blot was performed using Mini-
PROTEAN® Tetra Cell Systems (Bio-Rad) on 10% SDS-
PAGE. Proteins were electroblotted onto polyvinylidine 
difluoride (PVDF) membranes (Immobilon, Millipore) 
by semi-dry transfercell (Bio-Rad). Membranes were 
incubated with PTEN (D4.3) XP® rabbit monoclonal 
antibody (Cell Signaling) or PDCD4 (D29C6) XP® rabbit 
monoclonal antibody (Cell Signaling) or Phospho-Akt 
(Ser473) antibody (Cell Signaling) or Akt (C67E7) Rabbit 
monoclonal antibody (Cell Signaling) or phospho-IKKα/β 
(Ser176/180) (16A6) rabbit monoclonal antibody (Cell 
Signaling) or phospho-IκBα (Ser32/36) (5A5) mouse 
monoclonal antibody (Cell Signaling) or NF-κB p65 
(L8F6) mouse monoclonal antibody (Cell Signaling) or 
IKKα/β (H-470) rabbit polyclonal antibody (Santa Cruz) 
Table 5: Information of probe and primer for microRNA and gene measurement
MicroRNA/ 
Gene symbol UPL probe Forward primer (5ʹ–3ʹ) Reverse primer (5ʹ–3ʹ)
U6 61 ATGACACGCAAATTCGTGAAGC GCGAGCACAGAATTAATACGAC
hsa-miR-7-1 61 CAACAAATCACAGTCTGCCATA GCGAGCACAGAATTAATACGAC
hsa-miR-196a 61 TAGGTAGTTTCATGTTGTTGGG GCGAGCACAGAATTAATACGAC
hsa-miR-196b 61 TAGGTAGTTTCCTGTTGTTGGG GCGAGCACAGAATTAATACGAC
hsa-miR-744-3p 61 CTGTTGCCACTAACCTCAACCT GCGAGCACAGAATTAATACGAC
hsa-let-7a-3p 61 CTATACAATCTACTGTCTTTC GCGAGCACAGAATTAATACGAC
hsa-miR-34a-3p 61 CAATCAGCAAGTATACTGCCCT GCGAGCACAGAATTAATACGAC
hsa-miR-338 61 AACAATATCCTGGTGCTGAGTG GCGAGCACAGAATTAATACGAC
hsa-miR-365-5p 61 AGGGACTTTCAGGGGCAGCTGT GCGAGCACAGAATTAATACGAC
PTEN 59 GCTACCTGTTAAAGAATCATCTGGA CTGGCAGACCACAAACTGAG
PDCD4 10 TGGAAAGCGTAAAGATAGTGTGTG TTCTTTCAGCAGCATATCAATCTC
MMP-9 6 GAACCAATCTCACCGACAGG GCCACCCGAGTGTAACCATA
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or IκB-α (C-21) rabbit polyclonal antibody (Santa Cruz) 
at 1:1,000 dilution, or phospho-NF-κB p65 (Ser536) 
(93H1) rabbit monoclonal antibody (Cell Signaling) or 
MMP-9 (D6O3H) XP® Rabbit monoclonal antibody (Cell 
Signaling) at 1:500 dilution, or beta-actin specific antibody 
(Sigma-Aldrich) at 1:10,000 dilution at 4˚C overnight. 
Signals were developed using chemiluminescence Plus 
Western Blotting Detection System (Amersham) and 
analyzed using ImageJ software version 1.48 (http:/
rsbweb.nih.gov/ij/).
Argonaute 2 (Ago2) protein 
immunoprecipitation assay
Interaction between miR-744-3p and its target genes 
was confirmed by microRNA:mRNA immunoprecipitation 
using anti-Ago2 monoclonal antibody-immobilized beads 
(Wako) and human Argonaute 2 miRNA isolation kit 
(Wako Pure Chemical Industries). Expression levels of 
miR-744-3p, PTEN mRNA and PDCD4 mRNA within 
the Ago2-IP complex were quantitated by Real-time PCR 
on LightCycler® 480.
Luciferase reporter assay
The sense and antisense strands of the 3′-UTR of 
PTEN containing the binding sites of hsa-miR-744- 3p 
were synthesized. The oligonucleotides for wild-
type 3′-UTR of PTEN were as follows: sense strand: 
5′-CCACATCCTACCCCTTTGCACTGGCAACAGATA 
AGTTTGCAGTTGGCTAA-3′; antisense strand: 5′- AGC 
TTTAGCCAACTGCAAACTTATCTGTTGCCAGTGCA 
AAGGGGTAGGATGTGGACT-3′. The two single strands 
of the 3′- UTR of PTEN harboring a mutation in the 
binding sites of hsa-miR-744-3p were also synthesized. 
The oligonucleotides for mutant 3′-UTR of PTEN were 
as follows: sense strand: 5′-CCACATCCTACCCCTTT 
GCACCTATCGTCGATAAGTTTGCAGTTGGCTAA-3′; 
 antisense strand: 5′-AGCTTTAGCCAACTGCAAACTT 
ATCGACGATAGGTGCAAAGGGGTAGGATGTGGAG 
CT-3′. The sense and antisense strands of wild-type 
and mutant 3′-UTR of PTEN were annealed and cloned 
into the SacI and HindIII sites of the pMIR-REPORT 
Luciferase vector (Applied Biosystems) to generate Luc-
wild-type vector and Luc-mutant vector respectively. 
The Luciferase vectors containing the binding sites 
for miR-744-3p in 3′-UTR of PDCD4 with or without 
mutation were constructed using the above methods. 
The oligonucleotides for wild-type 3′-UTR of PDCD4 
were as follows: sense strand: 5′-CGGTGCCATTGCTC 
TCGTTTGGGCAACAAGAGTGAAACTCTTGTCTCA 
AAA-3′; antisense strand: 5′-AGCTTTTTGAGACAA 
GAGTTTCACTCTTGTTGCCCAAACGAGAGCAATG 
GCACCGAGCT-3′. The oligonucleotides for mutant 
3′-UTR of PDCD4 were as follows: sense strand: 5′-CGG 
TGCCATTGCTCTCGTTTGTATCGAGAGAGTGAAAC 
TCTTGTCTCAAAA-3′; antisense strand: 5′-AGCTTTTT 
GAGACAAGAGTTTCACTCTCTCGATACAAACGAG 
AGCAATGGCACCGAGCT-3′. MiR-744-3p silencing 
LSCC cells and their controls were seeded in 96 well 
plates for 24 hour before transfection. Cells were 
co- transfected with 50 ng of Luc-wild-type vector or 
Luc-mutant vector, along with 50 ng of pMIR-REPORT 
β-galactosidase control vector (Applied Biosystems) using 
Lipofectamine™ 2000 (Invitrogen). Firefly luciferase and 
β-galactosidase activities were measured 48 hour after 
transfection by Dual-Light luminescent reporter gene 
assay kit (Applied Biosystems, Waltham, Massachusetts, 
USA). Luciferase activity was normalized against 
β-galactosidase activity. The assay was performed in an 
LB 96V microplate luminometer (EG & G Berthold).
Animal models
LSCC cells (5 × 105) were injected intravenously 
into the tail veins of athymic nu/nu mice (5-weeks old, 
weight range: 18–22 g). The animals were euthanized 
on day 60 after injection and the lung were removed for 
histological examination. Hematoxylin and Eosin (H&E) 
staining was performed on the lung sections to evaluate 
the number of metastatic foci. The protocol for animal 
study was approved by the Institutional Committee on the 
Use of Live Animals in Teaching and Research (Protocol 
number 3675–15). 
Statistical analysis 
Statistical analyses were performed using the SPSS 
18.0 software package (SPSS Inc.). All results were presented 
as mean ± SE from three or more independent experiments. 
The difference between primary tumors and their normal 
counterparts was calculated by Wilcoxon Signed Rank 
test. Chi-square test and Pearson correlation test was used 
for evaluation on the clinical significance of microRNAs 
or genes in LSCC. The difference between control groups 
and engineered cell lines were analyzed used student-t-test. 
All the tests were 2-sided. Unless otherwise noted, P value 
< 0.05 was considered as statistically significant.
ACKNOWLEDGMENTS AND FUNDING
The study was support by Seed Funding for Basic 
Research, The University of Hong Kong.
CONFLICTS OF INTEREST 
No conflicts of interest were declared.
REFERENCES
1. Cattaruzza MS, Maisonneuve P, Boyle P. Epidemiology 
of laryngeal cancer. Eur J Cancer B Oral Oncol. 1996; 
32b:293–305.
Oncotarget58232www.impactjournals.com/oncotarget
 2. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world 
cancer burden: Globocan 2000. International journal of 
cancer. 2001; 94:153–6.
 3. Mirisola V, Mora R, Esposito AI, Guastini L, Tabacchiera F, 
Paleari L, Amaro A, Angelini G, Dellepiane M, Pfeffer U, 
Salami A. A prognostic multigene classifier for squamous cell 
carcinomas of the larynx. Cancer letters. 2011; 307:37–46.
 4. Belcher R, Hayes K, Fedewa S, Chen AY. Current treatment 
of head and neck squamous cell cancer. Journal of surgical 
oncology. 2014; 110:551–74. doi: 10.1002/jso.23724.
 5. Ferlito A, Haigentz M, Jr., Bradley PJ, Suarez C, Strojan P, 
Wolf GT, Olsen KD, Mendenhall WM, Mondin V, 
Rodrigo JP, Boedeker CC, Hamoir M, Hartl DM, et al. 
Causes of death of patients with laryngeal cancer. European 
archives of oto-rhino-laryngology. 2014; 271:425–34. doi: 
10.1007/s00405-013-2478-0.
 6. Kowalski LP. Lymph node metastasis as a prognostic factor 
in laryngeal cancer. Revista paulista de medicina. 1993; 
111:42–5.
 7. Esteller M. Non-coding RNAs in human disease. Nature 
reviews Genetics. 2011; 12:861–74. doi: 10.1038/nrg3074.
 8. Mendell JT. MicroRNAs: critical regulators of 
development, cellular physiology and malignancy. Cell 
cycle (Georgetown, Tex). 2005; 4:1179–84.
 9. Lin S, Gregory RI. MicroRNA biogenesis pathways in 
cancer. Nature reviews Cancer. 2015; 15:321–33. doi: 
10.1038/nrc3932.
10. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in 
cancer: rationale, strategies and challenges. Nature reviews 
Drug discovery. 2010; 9:775–89. doi: 10.1038/nrd3179.
11. Chen J, Li X. Expression of tumor suppressor gene PTEN 
in laryngeal carcinoma and its clinical significance. Journal 
of clinical otorhinolaryngology. 2006; 20:454–6.
12. Feng G, Li P, You H, Liu W, Zhang X, Xu X, Sun G, Li F. 
The expression and clinical pathological significance 
of PDCD in laryngocarcinoma. Journal of clinical 
otorhinolaryngology, head, and neck surgery. 2011; 25:16–9.
13. Wang J, Zhang Y. Expression of programmed cell death 
4 and its correlation with proliferation and apoptosis in 
laryngeal squamous cell carcinoma. Journal of clinical 
otorhinolaryngology, head, and neck surgery. 2012; 26:266–9.
14. Sun Z, Li S, Kaufmann AM, Albers AE. miR-21 increases 
the programmed cell death 4 gene-regulated cell proliferation 
in head and neck squamous carcinoma cell lines. Oncology 
reports. 2014; 32:2283–9. doi: 10.3892/or.2014.3456.
15. Cmarik JL, Min H, Hegamyer G, Zhan S, Kulesz-Martin M, 
Yoshinaga H, Matsuhashi S, Colburn NH. Differentially 
expressed protein Pdcd4 inhibits tumor promoter-induced 
neoplastic transformation. Proceedings of the National 
Academy of Sciences of the United States of America. 
1999; 96:14037–42.
16. Hilliard A, Hilliard B, Zheng SJ, Sun H, Miwa T, Song W, 
Goke R, Chen YH. Translational regulation of autoimmune 
inflammation and lymphoma genesis by programmed cell 
death 4. Journal of immunology (Baltimore, Md : 1950). 
2006; 177:8095–102.
17. Milella M, Falcone I, Conciatori F, Cesta Incani U, Del 
Curatolo A, Inzerilli N, Nuzzo CM, Vaccaro V, Vari S, 
Cognetti F, Ciuffreda L. PTEN: Multiple Functions in 
Human Malignant Tumors. Frontiers in oncology. 2015; 
5:24. doi: 10.3389/fonc.2015.00024.
18. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. 
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR 
complex. Science (New York, NY). 2005; 307:1098–101.
19. Parks WC, Wilson CL, Lopez-Boado YS. Matrix 
metalloproteinases as modulators of inflammation and innate 
immunity. Nature reviews Immunology. 2004; 4:617–29.
20. Wang R, Ma H, Lian M, Yang F, Wang H, Feng L, Fang J. 
A preliminary study on genome-wide expression profiling 
of laryngeal squamous cell carcinoma. Chinese journal of 
otorhinolaryngology head and neck surgery. 2014; 49:232–5.
21. Gong HL, Shi Y, Shi Y, Wu CP, Cao PY, Zhou L, Xu C. 
Reduced expression of mutS homolog 2 and mutL homolog 1 
affects overall survival in laryngeal squamous cell carcinoma 
patients: Investigation into a potential cause. Oncology 
reports. 2013; 30:1371–9. doi: 10.3892/or.2013.2559.
22. Ni RS, Shen X, Qian X, Yu C, Wu H, Gao X. Detection 
of differentially expressed genes and association with 
clinicopathological features in laryngeal squamous cell 
carcinoma. Oncology letters. 2012; 4:1354–60.
23. Shen X, Ni R, Qian X, Yu C, Wu H, Ni J, Zhu W, Gao X. 
A verification study on the genes associated with laryngeal 
squamous cell carcinoma by cDNA microarray. Journal of 
clinical otorhinolaryngology, head, and neck surgery. 2010; 
24:411–3.
24. Ma LJ, Li W, Zhang X, Huang DH, Zhang H, Xiao JY, 
Tian YQ. Differential gene expression profiling of laryngeal 
squamous cell carcinoma by laser capture microdissection 
and complementary DNA microarrays. Archives of medical 
research. 2009; 40:114–23. doi: 10.1016/j.arcmed.2008.12.005.
25. Colombo J, Fachel AA, De Freitas Calmon M, Cury PM, 
Fukuyama EE, Tajara EH, Cordeiro JA, Verjovski-
Almeida S, Reis EM, Rahal P. Gene expression profiling 
reveals molecular marker candidates of laryngeal squamous 
cell carcinoma. Oncology reports. 2009; 21:649–63.
26. Carinci F, Arcelli D, Lo Muzio L, Francioso F, Valentini D, 
Evangelisti R, Volinia S, D’Angelo A, Meroni G, Zollo M, 
Pastore A, Ionna F, Mastrangelo F, et al. Molecular 
classification of nodal metastasis in primary larynx squamous 
cell carcinoma. Translational research. 2007; 150:233–45.
27. Wang S, Liu F, Li X, Dong P. Research of the expression of 
PTEN in squamous cell carcinoma of larynx by the tissue 
chip technology. Journal of clinical otorhinolaryngology, 
head, and neck surgery. 2007; 21:1081–4.
28. Chen J, Tian YQ, Xiao JY. Difference expression of 
gene for laryngeal squamous cell carcinoma by cDNA 
microarray and signal pathways of cell cycle regulation and 
cell apoptosis. Journal of Central South University Medical 
sciences. 2005; 30:483–6.
Oncotarget58233www.impactjournals.com/oncotarget
29. Mriouah J, Boura C, Gargouri M, Plenat F, Faivre B. PTEN 
expression is involved in the invasive properties of HNSCC: 
a key protein to consider in locoregional recurrence. 
International journal of oncology. 2014; 44:709–16. doi: 
10.3892/ijo.2013.2219.
30. Gao Q, Zhang L, Zhang B, Wang QY, Sun CF, Dong XT, 
Ying J. Phosphatase and tensin homolog overexpression 
decreases proliferation and invasion and increases apoptosis 
in oral squamous cell carcinoma cells. Oncology letters. 
2014; 8:1058–64.
31. Zhu XL, Sun W, Lei WB, Zhuang HW, Hou WJ, Wen WP. 
DJ-1-induced phosphatase and tensin homologue 
downregulation is associated with proliferative and invasive 
activity of laryngeal cancer cells. Molecular medicine 
reports. 2015; 12:2003–8. doi: 10.3892/mmr.2015.3617.
32. Xie S, Lu Z, Lin Y, Shen L, Yin C. Upregulation of PTEN 
suppresses invasion in Tca8113 tongue cancer cells through 
repression of epithelial-mesenchymal transition (EMT). Tumour 
biology. 2016; 37:6681–9 doi: 10.1007/s13277-015-4486-8.
33. Reis PP, Tomenson M, Cervigne NK, Machado J, Jurisica I, 
Pintilie M, Sukhai MA, Perez-Ordonez B, Grenman R, 
Gilbert RW, Gullane PJ, Irish JC, Kamel-Reid S. Programmed 
cell death 4 loss increases tumor cell invasion and is regulated 
by miR-21 in oral squamous cell carcinoma. Molecular 
cancer. 2010; 9:238. doi: 10.1186/1476-4598-9-238.
34. Zhen Y, Liu Z, Yang H, Yu X, Wu Q, Hua S, Long X, 
Jiang Q, Song Y, Cheng C, Wang H, Zhao M, Fu Q, et al. 
Tumor suppressor PDCD4 modulates miR-184-mediated 
direct suppression of C-MYC, BCL2 blocking cell growth 
and survival in nasopharyngeal carcinoma. Cell death & 
disease. 2013; 4:e872. doi: 10.1038/cddis.2013.376.
35. Yang L, Shang X, Zhao X, Lin Y, Liu J. Correlation study 
between OPN, CD44v6, MMP-9 and distant metastasis 
in laryngeal squamous cell carcinoma. Journal of clinical 
otorhinolaryngology, head, and neck surgery. 2012; 26:989–92.
36. Zhang W, Liu Y, Wang CW. S100A4 promotes squamous 
cell laryngeal cancer Hep-2 cell invasion via NF-kB/
MMP- 9 signal. European review for medical and 
pharmacological sciences. 2014; 18:1361–7.
37. Gou X, Chen H, Jin F, Wu W, Li Y, Long J, Gong X, Luo M, 
Bi T, Li Z, He Q. Expressions of CD147, MMP-2 and 
MMP-9 in laryngeal carcinoma and its correlation with poor 
prognosis. Pathology oncology research. 2014; 20:475–481. 
doi: 10.1007/s12253-013-9720-3.
38. Guo X, Li W, Wang Q, Yang HS. AKT Activation by Pdcd4 
Knockdown Up-Regulates Cyclin D1 Expression and 
Promotes Cell Proliferation. Genes Cancer. 2011; 2:818– 28. 
doi: 10.1177/1947601911431082.
39. Bera A, Das F, Ghosh-Choudhury N, Kasinath BS, 
Abboud HE, Choudhury GG. microRNA-21-induced 
dissociation of PDCD4 from rictor contributes to Akt-
IKKbeta-mTORC1 axis to regulate renal cancer cell 
invasion. Experimental cell research. 2014; 328:99–117. 
doi: 10.1016/j.yexcr.2014.06.022.
40. Baud V, Karin M. Is NF-kappaB a good target for cancer 
therapy? Hopes and pitfalls. Nature reviews Drug discovery. 
2009; 8:33–40. doi: 10.1038/nrd2781.
41. Hwang SK, Baker AR, Young MR, Colburn NH. Tumor 
suppressor PDCD4 inhibits NF-kappaB-dependent 
transcription in human glioblastoma cells by direct 
interaction with p65. Carcinogenesis. 2014; 35:1469–80. 
doi: 10.1093/carcin/bgu008. 
42. Mora A, Komander D, van Aalten DM, Alessi DR. PDK1, 
the master regulator of AGC kinase signal transduction. 
Seminars in cell & developmental biology. 2004; 15:161–70.
43. Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway 
in cancer. Annual review of pathology. 2009; 4:127–50. doi: 
10.1146/annurev.pathol.4.110807.092311.
44. Vander Broek R, Mohan S, Eytan DF, Chen Z, Van Waes C. 
The PI3K/Akt/mTOR axis in head and neck cancer: 
functions, aberrations, cross-talk, and therapies. Oral 
diseases. 2015; 21:815–25. doi: 10.1111/odi.12206.
45. Gao W, Li JZ, Chan JY, Ho WK, Wong TS. mTOR 
Pathway and mTOR Inhibitors in Head and Neck 
Cancer. ISRN otolaryngology. 2012; 2012:953089. doi: 
10.5402/2012/953089.
46. Sansal I, Sellers WR. The biology and clinical relevance 
of the PTEN tumor suppressor pathway. Journal of clinical 
oncology. 2004; 22:2954–63.
47. Squarize CH, Castilho RM, Abrahao AC, Molinolo A, 
Lingen MW, Gutkind JS. PTEN deficiency contributes to 
the development and progression of head and neck cancer. 
Neoplasia (New York, NY). 2013; 15:461–71.
48. Simpson DR, Mell LK, Cohen EE. Targeting the PI3K/
AKT/mTOR pathway in squamous cell carcinoma of 
the head and neck. Oral oncology. 2015; 51:291–8. doi: 
10.1016/j.oraloncology.2014.11.012.
49. Horn D, Hess J, Freier K, Hoffmann J, Freudlsperger C. 
Targeting EGFR-PI3K-AKT-mTOR signaling enhances 
radiosensitivity in head and neck squamous cell carcinoma. 
Expert opinion on therapeutic targets. 2015; 19:795–805. 
doi: 10.1517/14728222.2015.1012157.
50. Ku JL, Kim WH, Lee JH, Park HS, Kim KH, Sung MW, 
Park JG. Establishment and characterization of human 
laryngeal squamous cell carcinoma cell lines. The 
Laryngoscope. 1999; 109:976–82.
51. Reichenstein I, Aizenberg N, Goshen M, Bentwich Z, 
Avni YS. A novel qPCR assay for viral encoded 
microRNAs. Journal of virological methods. 2010; 
163:323–8. doi: 10.1016/j.jviromet.2009.10.018.
52. Dweep H, Gretz N. miRWalk2.0: a comprehensive atlas 
of microRNA-target interactions. Nature methods. 2015; 
12:697. doi: 10.1038/nmeth.3485.
53. Betel D, Koppal A, Agius P, Sander C, Leslie C. 
Comprehensive modeling of microRNA targets predicts 
functional non-conserved and non-canonical sites. Genome 
biology. 2010; 11:R90. doi: 10.1186/gb-2010-11-8-r90.
